Oryzon Genomics S.A. Intangible Assets

The latest intangible assets for ORYZF is $120M as of June 2026. That compares with $100M in the prior-year period — up 16.2% year over year. Investors often review this figure alongside Oryzon Genomics S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ORYZF's intangible assets moved from $100M to $120M — a 16.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oryzon Genomics S.A.'s operating scale or balance-sheet position.

A intangible assets figure of $120M for ORYZF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ORYZF's intangible assets ($120M), review year-over-year change from $100M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Oryzon Genomics S.A.'s intangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.